RAMUCIRUMAB/PACLITAXEL THERAPY IN PATIENTS WITH ADVANCED GASTRIC CARCINOMA OR GASTROESOPHAGEAL JUNCTION (GEJ) **ADENOCARCINOMA IN THE CZECH REPUBLIC – PATIENT CHARACTERISTICS AND TREATMENT OUTCOMES**

VLADIMÍR HABĚTÍNEK¹, BOHUSLAV MELICHAR², RADKA OBERMANNOVÁ³, LENKA OSTŘÍŽKOVÁ⁴, JIŘÍ BARTOŠ⁵, LUBOŠ PETRUŽELKA⁶, LUCIE BROŽOVÁ⁷, KAREL HEJDUK⁷ ¹Eli Lilly and Company, Prague, Czech Republic, ²Department of Oncology, Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic, ³Masaryk Memorial Cancer Institute, Brno, Czech Republic, ³ ⁴Internal Hematology and Oncology, Regional Hospital Brno, Brno, Czech Republic, ⁵Department of Oncology, General University Hospital in Prague, Prague, Czech Republic, ⁶Department of Oncology, General University Hospital in Prague, Czech Republic, ⁶Department of Oncology, General University Hospital in Prague, Czech Republic, ⁶Department of Oncology, General University Hospital in Prague, Czech Republic, ⁶Department of Oncology, General University Hospital in Prague, Czech Republic, ⁶Department of Oncology, General University Hospital In Prague, Czech Republic, ⁶Department of Oncology, General University Hospital In Prague, Czech Republic, ⁶Department of Oncology, General University Hospital In Prague, Czech Republic, ⁶Department of Oncology, General University Hospital In Prague, Czech Republic, ⁶Department of Oncology, General University Hospital In Prague, Czech Republic, ⁶Department of Oncology, General University Hospital In Prague, Czech Republic, ⁶Department of Oncology, General University Hospital In Prague, Czech Republic, ⁶Department of Oncology, General University Hospital In Prague, Czech Republic, ⁶Department of Oncology, General University Hospital In Prague, Czech Republic, ⁶Department of Oncology, General University Hospital In Prague, Czech Republic, ⁶Department of Oncology, General University Hospital In Prague, Czech Republic, ⁶Department of Oncology, General University Hospital In Prague, Czech Republic, ⁶Department of Oncology, General University Hospital In Prague, Czech Republic, ⁶Department of Oncology, General University Hospital In Prague, Czech Republic, ⁶Department of Oncology, General University Hospital In Prague, Czech Republic, ⁶Department of Oncology, General University Hospital In Prague, Czech Republic, ⁶Department of Oncology, General University Hospital In Prague, Czech Republic, ⁶Department of Oncology, General University Hospital In Prague, Czech Republic, ⁶Department of Oncology, General University Hospital In Prague, Cze ⁷Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic

INTRODUCTION

- In the Czech Republic, real-world clinical practice data collection is a condition required for temporary drug reimbursement
- The Health Insurance Bureau in collaboration with The Institute of Biostatistics and Analyses from Masaryk University, Brno, initiated the 'CYRAMZA VILP' patient registry focusing on ramucirumab in combination with paclitaxel for the treatment of advanced gastric carcinoma or GEJ adenocarcinoma. Together, they conducted an independent assessment of the real-world outcomes of this treatment in patients meeting reimbursement criteria and treated under VILP reimbursement regimen, with the intention of informally examining whether the progression free survival (PFS) in the registry is in agreement with the PFS in the non-Asian subgroup of the phase 3 registrational trial, RAINBOW (NCT01170663)¹
- Here we report the registry outcomes based on data collected between February 1, 2018 and March 2, 2020 in light of the results from the non-Asian patient subgroup in the RAINBOW trial

OBJECTIVES & METHODOLOGY

Registry Design

Retrospective, non-interventional collection of data from treated patients

Reimbursement Criteria

- Ramucirumab plus paclitaxel combination treatment is reimbursed in adult patients with advanced stomach carcinoma or adenocarcinoma of GEJ, with disease progression after previous chemotherapy with the combination of platinum and fluoropyrimidine, and performance status Eastern Cooperative Oncology Group (ECOG) scale 0-1
- If it is necessary to suspend or discontinue the treatment with paclitaxel within the combined regimen due to paclitaxel toxicity, treatment with ramucirumab may continue if ramucirumab alone is well tolerated

Objectives


- Primary endpoint:
 - PFS (time from treatment initiation until the disease progression or death
- Secondary endpoints:
 - OS (time from treatment initiation till death from any reason);
 - Response to Treatment;
 - Safety of treatment (frequency and severity of adverse events)
- The PFS reported for the subgroup of n=221 patients from Europe, Israel, Australia, United States of America, Argentina, Brazil, Chile, and Mexico in the registrational trial, RAINBOW (Wilke et al., 2014¹, NCT01170663) was used as a benchmark.

Methods

- The data have been summarized by means of standard descriptive statistics and frequency tables; absolute and relative number in case of categorial variables, average (95% confidence interval, CI) and median with range (minimum–maximum) in case of continuous variables
- The description of OS, PFS and Time on Treatment has been done by means of Kaplan-Meier (KM) survival curves and corresponding medians and 95%CI
- 12th Prague Oncological Colloquium (PragueONCO 2021), Prague, Czech Republic; January 20 22, 2021


KEY RESULTS

PFS of patients treated within the VILP in the Czech Republic (n=127) and the non-Asian population from the registrational trial, RAINBOW (n=221)*




At time of analysis, disease progression or death were recorded in 89 (70.1%) of the total of 127 patients in the registry *Registry and clinical trial populations were not adjusted for patient characteristics

Baseline Demographics and Disease Charac	cteristics:	Baseline demographics and Disease Char	acteristics:	
Register VILP CYRAMZA	N = 127 (100%)	RAINBOW (Non-Asian, ramucirumab-treated population)		
	n (%) unless specified		N =221	
Sex	otherwise		n (%) unless specified	
Male	83 (65.4)	0	otherwise	
Female	44 (34.6)	Sex Male	156 (71)	
Age when starting treatment with ramucirumab, years		Female	65 (29)	
≤ 50	23 (18.1)	Age, years		
51–60 61–70	29 (22.8)	Median (min–max)	60 (25-83)	
> 70	47 (37.0) 28 (22.0)	Performance Status (ECOG)		
Average (95% CI)	62.0 (60.2–63.8)	0	73 (33)	
Median (min–max)	65 (38–78)	1	148 (67)	
Time of monitoring since the initiation of therapy (months)		Year of starting ramucirumab treatment ¹		
Average (95% CI)	5.5 (4.7–6.3)	2010	NR	
Median (min–max)	4.4 (0.0–18.7)	2011	NR	
Time from diagnosis till ramucirumab therapy initiation (months) Average (95% CI)	16.1(12.6–19.7)	2012	NR	
Median (min–max)	10.9 (2.4–185.0)	Number of metastatic sites		
Performance Status (ECOG)		0-2	127 (57)	
0	52 (40.9)	≥ 3 Presence of peritoneal metastases	94 (43)	
1	75 (59.1)	Yes	98 (44)	
Line of ramucirumab therapy (N = 126*)	110 (00 1)	Presence of ascites		
2nd line 3rd line and further	116 (92.1) 10 (7.9)	Yes	75 (34)	
Year of starting ramucirumab treatment	10 (1.5)			
2017	5 (3.9)	Abbreviations: Adverse events, AE; Confidence interval, CI;	Eastern Cooperative	
2018	55 (43.3)	Oncology Group, ECOG; gastroesophageal junction, GEJ; Kap	·	
2019	59 (46.5)	reported, NR; Overall survival, OS; Progression free survival, F	PFS; State Institute for	
2020	8 (6.3)	Drug Control, SÚKL; highly innovative drug product, VILP;		
Treatment with ramucirumab in combination with paclitaxel	1 (0.8)			
yes	126 (99.2)	References:		
Metastases at the time of starting treatment with ramucirumab	- ()	1. Wilke H, et al. Lancet Oncology 2014 Oct;15(11):1224-35		
no	3 (2.4)	2. Di Bartolomeo M, et al. Targeted Oncology 2018 Apr:13(2)2		
yes	124 (97.6)	3. Longo Munoz F. et al. Annals of Oncology 2019 Volume 30:		
Number of metastases (N = 122*)		4. Muro K, et al. Journal of Gastroenterology and Hepatology	2016;31: 581-589	
 < 3 metastatic lesions ≥ 3 metastatic lesions 	37 (30.3) 85 (69.7)	Disclosures. The Ourserse VIII Duranister was sure articles. D		
Peritoneal metastases (N = 122*)	00 (09.7)	Disclosures: The Cyramza VILP register was supported by El	-	
no	61 (50.0)	Habětínek is an Eli Lilly employee and shareholder. Dr. Melich from E. Lilly, Eisai, Bayer, Janssen, Pfizer, Astellas, Merck Ser	· ·	
yes	61 (50.0)	Servier and Sanofi; personal fees and non-financial support fr		
Ascites (N = 126*)		Amgen.		
no	102 (81.0)	Angen.		
Yes	24 (19.0)	Corresponding author email: habetinek_vladimir@lilly.com		
Weight, kg (N = 126*) Average (95% CI)	73.5 (70.7–76.2)			
Median (min–max)	70.5 (44.0–110.0)	· · · · · · · · · · · · · · · · · · ·		
Height, cm (N = 126*)	/	Acknowledgments: The CYRAMZA VILP registry was organized		
Average (95% CI)	173.0 (171.3–174.7)	like to thank all the oncology institutions in the Czech Republic,	who collaborated to co	
Median (min–max)	173.5 (150.0–197.0)	editorial contributions		



At time of analysis, there were 53 deaths (41.7%) from the total of 127 patients in the registry Median OS in non-Asian RAINBOW subgroup was 8.5 months (95% CI 7.4 - 9.8)* *Registry and clinical trial populations were not adjusted for patient characteristics



urance Bureau in collaboration with the Institute of Biostatistics and Analyses. We would collect the data. The authors would like to thank Philana Fernandes for her writing and

CONCLUSIONS

- effective

Course of Treatment with ramucirumab: Register VILP CYRAMZA

Ramucirumab-cor Change of dosage Treatment suspen Time to treatmen

Treatment discont

Reason for discon

Length of treatme

described using KM estimate of the probability of survival without an event

Real-world data indicate that reimbursed treatment of advanced gastric or GEJ adenocarcinoma with ramucirumab and paclitaxel in the Czech Republic is

Despite the limitations of this description (no formal comparisons or adjustments were made for differences between patient characteristics), reported outcomes from the ramucirumab and paclitaxel treatment registry appear to be generally consistent with the efficacy results for non-Asian patients in the registrational trial, RAINBOW and with previous published studies in real-life conditions from Europe^{1,2,3}

The low frequency of reported adverse events (3) evaluable reports out of 5 reported in total) may be due to non-obligatory reporting of safety data in this retrospective non-interventional patient registry

		N = 127 (100%)
		n (%) unless specified otherwise
ntaining regimen ng/kg by IV on the 1st and 15th day of the 28	8-dav cvcle	127 (100)
e		121 (100)
	No Yes ^a	126 (99.2) 1 (0.8)
nsion		
	No Yes ^b	120 (94.5) 7 (5.5)
t failure ^c (months)		
KM survival estimate : media	n (95% CI)	3.4 (2.7-4.1)
tinued		
	No yes	35 (27.6) 92 (72.4)
ntinuation (n=92)		
Status deterioration without p	orogression progression Death er reasons ^d	69 (75) 15 (16.3) 3 (3.3) 5 (5.4)
ent (months) (n=92)		
Averag	e (95% CI) (min–max)	3.9 (3.2-4.6) 2.9 (0.0-17.7)

^a The dose for the patient was changed due to thrombocytopenia ^b Reasons included a request for reimbursement, neutropenia and stomatological intervention

^c Time to treatment failure describes the time interval from treatment initiation until its discontinuation for any reason;

^d Examples include disease stabilization, hepatorenal failure and urosepsis



Scan for full poster and slide deck https://lillyscience.lilly.com/congress/pragueonco202

Sponsored by Eli Lilly and Company